[MeMed in GlobeNewsWire] Prospective Study Finds Potential Utility of MeMed’s Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients

Researchers at Israel’s Rabin Medical Center (comprised of Beilinson and Hasharon Hospitals) in collaboration with MeMed, have published prospective data on the potential utility of the analysis of IP-10, a host immune biomarker, in managing the care and treatment of patients with severe COVID-19 infection.

Read more here.

The post [MeMed in GlobeNewsWire] Prospective Study Finds Potential Utility of MeMed’s Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients appeared first on OurCrowd Blog.

OurCrowd Blog